David Taber

1.6k total citations
28 papers, 1.2k citations indexed

About

David Taber is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Organic Chemistry. According to data from OpenAlex, David Taber has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 5 papers in Organic Chemistry. Recurrent topics in David Taber's work include Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (6 papers) and Renal cell carcinoma treatment (5 papers). David Taber is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (6 papers) and Renal cell carcinoma treatment (5 papers). David Taber collaborates with scholars based in United States. David Taber's co-authors include Walter M. Stadler, Everett E. Vokes, Nicholas J. Vogelzang, Hedy L. Kindler, Theodore Karrison, Mark Kozloff, D. A. Singh, Sreenivasa Nattam, Abraham H. Dachman and Gershon Y. Locker and has published in prestigious journals such as Science, Journal of the American Chemical Society and Journal of Clinical Oncology.

In The Last Decade

David Taber

28 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Taber United States 11 643 475 445 280 90 28 1.2k
Alton B. Kremer United States 11 551 0.9× 850 1.8× 660 1.5× 405 1.4× 93 1.0× 13 1.4k
Tomohide Tamura Japan 19 522 0.8× 267 0.6× 726 1.6× 213 0.8× 56 0.6× 44 1.2k
C.J.A. van Moorsel Netherlands 14 644 1.0× 333 0.7× 445 1.0× 141 0.5× 157 1.7× 16 1.1k
V. Damiano Italy 15 796 1.2× 568 1.2× 502 1.1× 181 0.6× 105 1.2× 34 1.3k
Chung-Tsen Hsueh United States 19 556 0.9× 305 0.6× 416 0.9× 200 0.7× 112 1.2× 55 1.2k
D. Von Hoff United States 11 1.1k 1.7× 387 0.8× 540 1.2× 406 1.4× 125 1.4× 24 1.5k
D. J. Th. Wagener Netherlands 18 506 0.8× 401 0.8× 311 0.7× 154 0.6× 236 2.6× 57 1.1k
Francisco Javier Ramos Spain 15 625 1.0× 422 0.9× 771 1.7× 192 0.7× 136 1.5× 42 1.4k
Cecilia Nisticò Italy 23 1.2k 1.9× 403 0.8× 306 0.7× 555 2.0× 61 0.7× 70 1.6k
Edgardo S. Santos United States 21 576 0.9× 524 1.1× 384 0.9× 230 0.8× 88 1.0× 101 1.2k

Countries citing papers authored by David Taber

Since Specialization
Citations

This map shows the geographic impact of David Taber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Taber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Taber more than expected).

Fields of papers citing papers by David Taber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Taber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Taber. The network helps show where David Taber may publish in the future.

Co-authorship network of co-authors of David Taber

This figure shows the co-authorship network connecting the top 25 collaborators of David Taber. A scholar is included among the top collaborators of David Taber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Taber. David Taber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jalal, Shadia I., Tareq Al Baghdadi, Sumeet Bhatia, et al.. (2012). Erlotinib and Bevacizumab in Newly Diagnosed Performance Status 2 or Elderly Patients With Nonsquamous Non–Small-Cell Lung Cancer, a Phase II Study of the Hoosier Oncology Group: LUN04-77. Clinical Lung Cancer. 14(3). 224–229. 8 indexed citations
2.
Kindler, Hedy L., Theodore Karrison, David R. Gandara, et al.. (2012). Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma. Journal of Clinical Oncology. 30(20). 2509–2515. 144 indexed citations
3.
Sharma, Manish, Kristen Wroblewski, Blasé N. Polite, et al.. (2011). Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Investigational New Drugs. 30(3). 1211–1215. 43 indexed citations
4.
Sharma, Monica, Kristen Wroblewski, Mark Kozloff, et al.. (2011). Dasatinib (D) in previously treated metastatic colorectal cancer (mCRC) patients: A phase II trial of the University of Chicago phase II consortium.. Journal of Clinical Oncology. 29(4_suppl). 506–506. 3 indexed citations
5.
Nimeiri, Halla, D. A. Singh, Kristen Kasza, et al.. (2009). The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium. Investigational New Drugs. 28(6). 854–858. 5 indexed citations
6.
Choong, Nicholas W., Mark Kozloff, David Taber, et al.. (2009). Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Investigational New Drugs. 28(5). 677–683. 59 indexed citations
7.
Fisher, William B., Daniel Bruetman, J. McClean, et al.. (2008). Gefitinib Plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group. Journal of Thoracic Oncology. 3(4). 374–379. 19 indexed citations
8.
Singh, D. A., David Taber, Rafat Ansari, et al.. (2006). A phase II trial of the epothilone B analog BMS-247550 in patients (pts) with hepatobiliary cancer (HBC): An updated analysis. Journal of Clinical Oncology. 24(18_suppl). 14050–14050. 10 indexed citations
9.
Desai, Apurva A., Hedy L. Kindler, David Taber, et al.. (2005). Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemotherapy and Pharmacology. 56(4). 421–426. 14 indexed citations
10.
Gupta, Supriya, Ann M. Mauer, Christopher W. Ryan, et al.. (2005). A Phase II Trial of UFT and Leucovorin in Women 65 Years and Older With Advanced Breast Cancer. American Journal of Clinical Oncology. 28(1). 65–69. 6 indexed citations
11.
Kindler, Hedy L., Gregory Friberg, D. A. Singh, et al.. (2005). Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology. 23(31). 8033–8040. 360 indexed citations
12.
Mauer, Ann M., Rafat Ansari, P C Hoffman, et al.. (2003). Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer. Annals of Oncology. 14(5). 722–728. 3 indexed citations
13.
Rini, Brian I., et al.. (2000). Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer. Journal of Clinical Oncology. 18(12). 2419–2426. 121 indexed citations
14.
Stadler, Walter M., Nicholas J. Vogelzang, Robert J. Amato, et al.. (2000). Flavopiridol, A Novel Cyclin-Dependent Kinase Inhibitor, in Metastatic Renal Cancer: A University of Chicago Phase II Consortium Study. Journal of Clinical Oncology. 18(2). 371–371. 167 indexed citations
15.
Taber, David, et al.. (1972). Assessing detergent safety: A comparison of a nonphosphate laundry detergent with phosphate detergents. Journal of the American Oil Chemists Society. 49(10). 539–551. 7 indexed citations
16.
Taber, David, et al.. (1969). Bacteriostatic effectiveness of 1-acyl-3-(3,4-dichlorophenyl)ureas. Journal of Medicinal Chemistry. 12(4). 707–708. 1 indexed citations
17.
Taber, David, et al.. (1967). The microbiological availability of soap bacteriostats. Journal of the American Oil Chemists Society. 44(8). 473–475. 3 indexed citations
18.
Jungermann, Eric, et al.. (1967). Comparative evaluation of antibacterial soaps. Journal of the American Oil Chemists Society. 44(4). 232–234. 5 indexed citations
19.
Kosak, Alvin I., et al.. (1957). Stigmasterol in Cigarette Smoke. Science. 125(3255). 991–992. 4 indexed citations
20.
Kosak, Alvin I., et al.. (1956). The Components of Cigarette Smoke. I. Preliminary Studies<xref ref-type="fn" rid="fn1">2</xref>. JNCI Journal of the National Cancer Institute. 17(3). 375–89. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alton B. Kremer Breakdown of academic impact, for papers by Tomohide Tamura Breakdown of academic impact, for papers by C.J.A. van Moorsel Breakdown of academic impact, for papers by V. Damiano Breakdown of academic impact, for papers by Chung-Tsen Hsueh Breakdown of academic impact, for papers by D. Von Hoff Breakdown of academic impact, for papers by D. J. Th. Wagener Breakdown of academic impact, for papers by Francisco Javier Ramos Breakdown of academic impact, for papers by Cecilia Nisticò Breakdown of academic impact, for papers by Edgardo S. Santos
Rankless by CCL
2026